Two-Year Trends of Taxane-Induced Neuropathy in Women Enrolled in a Randomized Trial of Acetyl-L-Carnitine (SWOG S0715)

• Published in: JNCI : Journal of the National Cancer Institute Vol. 110; no. 6; pp. 669 - 676
• Main Authors: Hershman, Dawn L, Unger, Joseph M, Crew, Katherine D, Till, Cathee, Greenlee, Heather, Minasian, Lori M, Moinpour, Carol M, Lew, Danika L, Fehrenbacher, Louis, Wade, James L, Wong, Siu-Fun, Fisch, Michael J, Lynn Henry, N, Albain, Kathy S
• Format: Journal Article
• Language: English
• Published: United States Oxford University Press 01.06.2018
• Subjects: Acetylcarnitine - administration & dosage; Adult; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Breast Neoplasms - drug therapy; Breast Neoplasms - epidemiology; Chemotherapy, Adjuvant; Dietary Supplements; Docetaxel - administration & dosage; Docetaxel - adverse effects; Double-Blind Method; Female; Humans; Middle Aged; Neurotoxicity Syndromes - epidemiology; Neurotoxicity Syndromes - prevention & control; Paclitaxel - administration & dosage; Paclitaxel - adverse effects; Placebos; Taxoids - administration & dosage; Taxoids - adverse effects; Treatment Outcome

Abstract Background Chemotherapy-induced peripheral neuropathy (CIPN) is a common and disabling side effect of taxanes. Acetyl-L-carnitine (ALC) was unexpectedly found to increase CIPN in a randomized trial. We investigated the long-term patterns of CIPN among patients in this trial. Methods S0715 w...